Evidence map›Paper›PMID 39768484›Full record

ReviewJournal of clinical medicine2024

MicroRNA and Heart Failure: A Novel Promising Diagnostic and Therapeutic Tool.

Andrea D'Amato, Silvia Prosperi, Paolo Severino, Vincenzo Myftari, Michele Correale, Pasquale Perrone Filardi, Roberto Badagliacca, Francesco Fedele, Carmine Dario Vizza, Alberto Palazzuoli and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea D'AmatoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.ORCID 0000-0001-8227-2154
Silvia ProsperiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.
Paolo SeverinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.ORCID 0000-0001-6211-4482
Vincenzo MyftariDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.
Michele CorrealeCardiothoracic Department, 'Policlinico Riuniti' University Hospital, 71100 Foggia, Italy.ORCID 0000-0002-7863-253X
Pasquale Perrone FilardiDepartment of Advanced Biomedical Sciences, Section of Cardiology, Federico II University, 80131 Naples, Italy.
Roberto BadagliaccaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.ORCID 0000-0002-7887-5961
Francesco FedeleIRCCS San Raffaele Cassino, 03043 Cassino, Italy.
Carmine Dario VizzaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, 'Sapienza' University of Rome, Policlinico 'Umberto I' of Rome, 00161 Rome, Italy.ORCID 0000-0002-3540-4983
Alberto PalazzuoliCardio Thoracic and Vascular Department, 'S. Maria alle Scotte Hospital', University of Siena, 53100 Siena, Italy.ORCID 0000-0002-6235-984X
Heart Failure Working Group of the Italian Society of Cardiology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) has a multifaceted and complex pathophysiology. Beyond neurohormonal, renin-angiotensin-aldosterone system, and adrenergic hyperactivation, a role for other pathophysiological determinants is emerging. Genetic and epigenetic factors are involved in this syndrome. In many maladaptive processes, the role of microRNAs (miRNAs) has been recently demonstrated. MiRNAs are small endogenous non-coding molecules of RNA involved in gene expression regulation, and they play a pivotal role in intercellular communication, being involved in different biological and pathophysiological processes. MiRNAs can modulate infarct area size, cardiomyocytes restoration, collagen deposition, and macrophage polarization. MiRNAs may be considered as specific biomarkers of hypertrophy and fibrosis. MiRNAs have been proposed as a therapeutical tool because their administration can contrast with myocardial pathophysiological remodeling leading to HF. Antimir and miRNA mimics are small oligonucleotides which may be administered in several manners and may be able to regulate the expression of specific and circulating miRNAs. Studies on animal models and on healthy humans demonstrate that these molecules are well tolerated and effective, opening the possibility of a therapeutic use of miRNAs in cases of HF. The application of miRNAs for diagnosis, prognostic stratification, and therapy fits in with the new concept of a personalized and tailored approach to HF.

Indexed as

biomarkersdiagnosisfibrosisheart failurehypertrophymiRNAstherapy

Identifiers

PMID39768484
PMCPMC11728316

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.